Acute myeloid leukemia
Conditions
Interventions
Age under 60:GCSF 300ug d0-d5, Cladribine 5mg/m2, d1-5, cytarabine 2g/m2 qd, d1-5, homoharringtonine 2mg/m2d1-d5.
Age over 60:GCSF 300ug d0-d5, azacytidine 100mg, d1-5, cedarabine 10mg qd, d1-28, cytarabine 10mg/m2 q12h, d3-9, homoharringtonine 1mg d3-d9.
Sponsors
Sichuan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Recurrent AML: Leukemia cells or primordial cells in bone marrow recurred in peripheral blood after CR > 0.05 (except for bone marrow regeneration after consolidation chemotherapy) or extramedullary leukemia cell infiltration; 2. Diagnostic criteria for refractory AML: Initial cases ineffective after two courses of treatment with standard regimen: those who relapse within 12 months after CR after consolidation and intensive treatment; those who relapse after 12 months but fail to respond to conventional chemotherapy; those who relapse twice or more; those with persistent extramedullary leukemia.
Exclusion criteria
Exclusion criteria: 1. Patients with cardiac insufficiency: ejection fraction (EF) 2 mg/dl (34.2 micromol/L), AST > 2.5 times the normal upper limit, serum creatinine (SCr) > 2.5 mg/dl (221 micromol/L).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Influencing Factors of Drug Resistance; | — |
Countries
China
Contacts
Public ContactLi Hui
Sichuan People's Hospital
Outcome results
None listed